Bridge Biotherapeutics, Inc. (KOSDAQ:288330)
South Korea
· Delayed Price · Currency is KRW 6,080.00
-20.00 (-0.33%)
At close: Mar 21, 2025, 3:30 PM KST
Bridge Biotherapeutics Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2019 |
| Net Income | -19,756 | -42,321 | -41,700 | -26,278 | -19,232 | Upgrade
|
| Depreciation & Amortization | 1,432 | 1,424 | 1,078 | 381.46 | 357.87 | Upgrade
|
| Loss (Gain) From Sale of Assets | 22.97 | - | - | - | 1.05 | Upgrade
|
| Asset Writedown & Restructuring Costs | 521.15 | - | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | 50.78 | 26.78 | -51.29 | -0.3 | -186.87 | Upgrade
|
| Stock-Based Compensation | 349.16 | 2,645 | 3,546 | 3,292 | 1,412 | Upgrade
|
| Other Operating Activities | 494.7 | 3,073 | -1,644 | -24.62 | 2,722 | Upgrade
|
| Change in Accounts Receivable | -1.1 | -100 | - | 572.25 | -573.23 | Upgrade
|
| Change in Inventory | - | - | - | - | 1,933 | Upgrade
|
| Change in Accounts Payable | - | -0.07 | - | - | - | Upgrade
|
| Change in Other Net Operating Assets | -3,829 | 3,476 | -1,411 | 929 | 529.83 | Upgrade
|
| Operating Cash Flow | -20,715 | -31,775 | -40,182 | -21,128 | -13,037 | Upgrade
|
| Capital Expenditures | -1.43 | -319.51 | -437.05 | -164.87 | -79.75 | Upgrade
|
| Sale of Property, Plant & Equipment | 7.03 | - | - | - | 0.59 | Upgrade
|
| Cash Acquisitions | - | -3,787 | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -138.63 | -49.25 | -0.81 | -3.8 | - | Upgrade
|
| Investment in Securities | -10,108 | 37,073 | -8,484 | 2,123 | -31,775 | Upgrade
|
| Other Investing Activities | - | -0 | 0 | -0 | - | Upgrade
|
| Investing Cash Flow | -10,241 | 32,917 | -8,922 | 1,955 | -31,854 | Upgrade
|
| Long-Term Debt Repaid | -618.47 | -1,024 | -763.67 | -168.14 | -176.04 | Upgrade
|
| Net Debt Issued (Repaid) | -618.47 | -1,024 | -763.67 | -168.14 | -176.04 | Upgrade
|
| Issuance of Common Stock | 23,021 | 3,155 | 828.87 | 6,194 | 2,087 | Upgrade
|
| Repurchase of Common Stock | -10.33 | - | - | - | - | Upgrade
|
| Other Financing Activities | 67.8 | -12.05 | -0 | - | -51.25 | Upgrade
|
| Financing Cash Flow | 22,460 | 5,086 | 48,643 | 6,026 | 1,859 | Upgrade
|
| Foreign Exchange Rate Adjustments | 50.45 | 12.32 | 203.42 | 404.81 | -112.42 | Upgrade
|
| Net Cash Flow | -8,446 | 6,240 | -257.8 | -12,743 | -43,144 | Upgrade
|
| Free Cash Flow | -20,716 | -32,095 | -40,619 | -21,293 | -13,117 | Upgrade
|
| Free Cash Flow Margin | -951137.57% | -32094.94% | -1343.35% | -1106.61% | -206.90% | Upgrade
|
| Free Cash Flow Per Share | -508.58 | -1070.06 | -1706.25 | -908.42 | -573.78 | Upgrade
|
| Cash Interest Paid | 149 | 167.6 | 64.51 | 7.53 | 6.34 | Upgrade
|
| Cash Income Tax Paid | -149.57 | 126.74 | 32.69 | -4.88 | -2,662 | Upgrade
|
| Levered Free Cash Flow | -17,056 | -16,679 | -22,289 | -9,435 | -7,027 | Upgrade
|
| Unlevered Free Cash Flow | -16,938 | -16,572 | -22,248 | -9,431 | -7,023 | Upgrade
|
| Change in Net Working Capital | 6,699 | -4,945 | -754.39 | -3,559 | -3,524 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.